Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab Safety Extension in Severe Asthma (DESTINATION)
NCT03706079Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2019
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of tezepelumab in asthma, sponsored by AstraZeneca. Started Jan 2019; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03706079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706079.